Amneal Operating Income from 2010 to 2024

AMRX Stock

USD 9.03 0.22 2.38%

Amneal Pharmaceuticals, Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income will likely drop to about 122.7 M in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Amneal Pharmaceuticals, Class generates from its operations. View All Fundamentals

Operating Income

First Reported

2016-12-31

Previous Quarter

95.5 M

Current Value

88.8 M

Quarterly Volatility

61.9 M

Covid

Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.

Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Operating Income Growth Pattern

Below is the plot of the Operating Income of Amneal Pharmaceuticals, Class over the last few years. Operating Income is the amount of profit realized from Amneal Pharmaceuticals, operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amneal Pharmaceuticals, Class is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Amneal Pharmaceuticals,'s Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Amneal Operating Income Regression Statistics

	Arithmetic Mean	169,920,008
	Geometric Mean	167,701,425
	Coefficient Of Variation	66.57
	Mean Deviation	83,050,388
	Median	222,942,000
	Standard Deviation	113,109,527
	Sample Variance	12793.8T
	Range	422.3M
	R-Value	(0.34)
	Mean Square Error	12222.7T
	R-Squared	0.11
	Significance	0.22
	Slope	(8,497,268)
	Total Sum of Squares	179112.7T

Amneal Operating Income History

	2024	122.7 M
	2023	204.4 M
	2022	206.5 M
	2021	209.2 M
	2020	91.2 M
	2019	-137.4 M
	2018	-19.7 M

Other Fundumenentals of Amneal Pharmaceuticals,

Non Operating Income Net Other

Amneal Pharmaceuticals, Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.88	-0.95	0.89	-0.28	0.87	0.91	0.84	0.93	-0.78	0.93	0.65	0.94	0.32	0.92	0.24	0.37	0.96	0.86	0.73	0.6	0.96	0.85	0.25	-0.21
Total Stockholder Equity	0.88		-0.85	0.73	0.1	0.86	0.79	0.62	0.74	-0.64	0.8	0.33	0.8	0.02	0.76	-0.01	0.06	0.93	0.67	0.65	0.25	0.84	0.79	0.04	0.01
Net Tangible Assets	-0.95	-0.85		-0.96	0.43	-0.87	-0.98	-0.91	-0.94	0.9	-0.97	-0.71	-0.98	-0.43	-0.96	-0.29	-0.48	-0.99	-0.93	-0.87	-0.68	-0.99	-0.87	-0.34	0.3
Net Debt	0.89	0.73	-0.96		-0.57	0.81	0.99	0.95	0.95	-0.96	0.97	0.81	0.98	0.53	0.96	0.35	0.58	0.92	0.92	0.91	0.72	0.95	0.8	0.33	-0.3
Retained Earnings	-0.28	0.1	0.43	-0.57		-0.13	-0.5	-0.65	-0.52	0.6	-0.49	-0.81	-0.49	-0.81	-0.5	-0.63	-0.83	-0.27	-0.61	-0.55	-0.85	-0.42	-0.23	-0.58	0.6
Accounts Payable	0.87	0.86	-0.87	0.81	-0.13		0.85	0.78	0.82	-0.76	0.82	0.46	0.85	-0.02	0.84	-0.16	0.04	0.89	0.67	0.67	0.47	0.86	0.87	-0.04	0.17
Long Term Debt	0.91	0.79	-0.98	0.99	-0.5	0.85		0.95	0.95	-0.95	0.98	0.78	0.99	0.48	0.98	0.31	0.53	0.95	0.92	0.92	0.7	0.97	0.85	0.33	-0.29
Net Receivables	0.84	0.62	-0.91	0.95	-0.65	0.78	0.95		0.96	-0.9	0.95	0.88	0.96	0.55	0.96	0.38	0.61	0.84	0.91	0.86	0.84	0.92	0.78	0.39	-0.33
Good Will	0.93	0.74	-0.94	0.95	-0.52	0.82	0.95	0.96		-0.84	0.98	0.86	0.98	0.51	0.98	0.42	0.56	0.9	0.92	0.79	0.78	0.96	0.81	0.34	-0.32
Short Term Investments	-0.78	-0.64	0.9	-0.96	0.6	-0.76	-0.95	-0.9	-0.84		-0.89	-0.73	-0.91	-0.5	-0.9	-0.26	-0.54	-0.84	-0.85	-0.95	-0.69	-0.87	-0.78	-0.33	0.28
Long Term Debt Total	0.93	0.8	-0.97	0.97	-0.49	0.82	0.98	0.95	0.98	-0.89		0.82	0.99	0.49	0.98	0.41	0.54	0.95	0.93	0.88	0.72	0.97	0.81	0.32	-0.31
Capital Surpluse	0.65	0.33	-0.71	0.81	-0.81	0.46	0.78	0.88	0.86	-0.73	0.82		0.8	0.77	0.82	0.71	0.81	0.61	0.82	0.72	0.87	0.73	0.51	0.45	-0.51
Total Liab	0.94	0.8	-0.98	0.98	-0.49	0.85	0.99	0.96	0.98	-0.91	0.99	0.8		0.49	0.99	0.35	0.54	0.95	0.94	0.87	0.73	0.98	0.86	0.35	-0.31
Short Long Term Debt	0.32	0.02	-0.43	0.53	-0.81	-0.02	0.48	0.55	0.51	-0.5	0.49	0.77	0.49		0.5	0.88	1.0	0.3	0.69	0.52	0.68	0.46	0.24	0.81	-0.88
Total Current Assets	0.92	0.76	-0.96	0.96	-0.5	0.84	0.98	0.96	0.98	-0.9	0.98	0.82	0.99	0.5		0.35	0.55	0.92	0.93	0.84	0.76	0.97	0.89	0.36	-0.32
Treasury Stock	0.24	-0.01	-0.29	0.35	-0.63	-0.16	0.31	0.38	0.42	-0.26	0.41	0.71	0.35	0.88	0.35		0.87	0.2	0.53	0.35	0.55	0.32	0.05	0.61	-0.8
Short Term Debt	0.37	0.06	-0.48	0.58	-0.83	0.04	0.53	0.61	0.56	-0.54	0.54	0.81	0.54	1.0	0.55	0.87		0.36	0.73	0.55	0.73	0.51	0.29	0.81	-0.87
Intangible Assets	0.96	0.93	-0.99	0.92	-0.27	0.89	0.95	0.84	0.9	-0.84	0.95	0.61	0.95	0.3	0.92	0.2	0.36		0.88	0.82	0.57	0.97	0.87	0.26	-0.2
Common Stock	0.86	0.67	-0.93	0.92	-0.61	0.67	0.92	0.91	0.92	-0.85	0.93	0.82	0.94	0.69	0.93	0.53	0.73	0.88		0.82	0.81	0.95	0.81	0.64	-0.6
Property Plant Equipment	0.73	0.65	-0.87	0.91	-0.55	0.67	0.92	0.86	0.79	-0.95	0.88	0.72	0.87	0.52	0.84	0.35	0.55	0.82	0.82		0.61	0.82	0.68	0.33	-0.32
Current Deferred Revenue	0.6	0.25	-0.68	0.72	-0.85	0.47	0.7	0.84	0.78	-0.69	0.72	0.87	0.73	0.68	0.76	0.55	0.73	0.57	0.81	0.61		0.71	0.6	0.59	-0.56
Net Invested Capital	0.96	0.84	-0.99	0.95	-0.42	0.86	0.97	0.92	0.96	-0.87	0.97	0.73	0.98	0.46	0.97	0.32	0.51	0.97	0.95	0.82	0.71		0.9	0.41	-0.35
Net Working Capital	0.85	0.79	-0.87	0.8	-0.23	0.87	0.85	0.78	0.81	-0.78	0.81	0.51	0.86	0.24	0.89	0.05	0.29	0.87	0.81	0.68	0.6	0.9		0.35	-0.22
Capital Stock	0.25	0.04	-0.34	0.33	-0.58	-0.04	0.33	0.39	0.34	-0.33	0.32	0.45	0.35	0.81	0.36	0.61	0.81	0.26	0.64	0.33	0.59	0.41	0.35		-0.96
Long Term Investments	-0.21	0.01	0.3	-0.3	0.6	0.17	-0.29	-0.33	-0.32	0.28	-0.31	-0.51	-0.31	-0.88	-0.32	-0.8	-0.87	-0.2	-0.6	-0.32	-0.56	-0.35	-0.22	-0.96

Click cells to compare fundamentals

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	204.4 M	122.7 M
Non Operating Income Net Other	4.7 M	4.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Operating Income from 2010 to 2024

Latest Amneal Pharmaceuticals,'s Operating Income Growth Pattern

Amneal Operating Income Regression Statistics

Amneal Operating Income History

Other Fundumenentals of Amneal Pharmaceuticals,

Amneal Pharmaceuticals, Operating Income component correlations

About Amneal Pharmaceuticals, Financial Statements

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY